Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte’s powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaking move in the field of endometriosis. Hera Biotech is set to acquire and bring to the patients Scailyte’s endometriosis diagnostic assets, marking a significant milestone in non-surgical diagnosis of endometriosis.

Leveraging the biggest single-cell RNAseq dataset in endometriosis and our best-in-class biomarker discovery platform, ScaiVision, we have identified highly accurate biomarkers for the diagnosis of endometriosis. Unlike conventional methods for analysis and interpretation of single-cell data that start with cell clustering and cell type annotation, ScaiVision is using an unbiased representation learning method that allows ultra-sensitive discovery of novel biology. 

Following the discovery of the disease-associated gene signatures and cell phenotypes from single-cell data, we went through several translational steps and prototyped a conventional and scalable qPCR assay, which Hera Biotech will now validate further and deploy in clinical laboratories in the USA. 

Reach out if you want to learn more about ScaiVision and how we can partner to make groundbreaking discoveries leveraging multi-omics data and our proprietary AI platform!